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Microbubbles have proven to be useful as diagnostic
agents for ultrasound[1,2]. However, they have the
potential for a far wider range of uses, both in unmodi-
fied form (thus minimising regulatory barriers) and in
new forms[3]. These future uses may be divided into
diagnostic and therapeutic categories.
Routine diagnostic uses of microbubbles relevant to
oncology are mainly in the liver, where they have been
endorsed by NICE for the characterisation of focal liver
lesions[4]. The key attribute here is the fact that malig-
nancies do not have the functioning sinusoidal system
that accounts for the late retention of microbubbles in
the normal liver and in solid focal lesions - in this appli-
cation, microbubbles are as effective as CT with contrast
but less costly. Many similar oncological uses exploit
microbubbles’ exquisite ability to define both the
macro- and microvasculature of tissue. Examples include
characterising BI-RADS 3 and 4a breast masses, distin-
guishing pancreatic adenocarcinoma (hypoperfused)
from focal pancreatitis (well perfused) and distinguishing
complex-appearing real cysts from cystic carcinomas.
A potentially important extension is to develop targeted
microbubbles that attach preferentially to cell surface
molecules of interest[5]. Since conventional microbubbles
of micron diameter cannot escape from the blood pool,
the initial target is the blood vasculature. Ligands to
VEGF1 can be attached to microbubbles; numerous precli-
nical studies have shown these to be effective ways to
image malignant neovascularisation and the first human
trial in prostate cancer has been completed[6]. A difficulty
has been the relatively poor binding power of the targeted
microbubbles, especially in the non-immunogenic form
suitable for human use. The same strategies that are used
for molecular imaging in nuclear medicine and MR can be
deployed: improve the specific binding or wait for clear-
ance of the unbound agent from the blood stream.
Another approach makes use of the fast time resolution of
ultrasound and tries to recognise which microbubbles are
fixed and which are moving, thus enabling the bound
population to be selectively imaged. Efforts have also been
made to detect differences in the echoes from free versus
bound microbubbles.
An important advance in allowing access to tissue
beyond the endothelium is the development of nanodro-
plets, made by cooling and pressurising microbubbles - at
around 200nm in diameter, they are able to cross the
endothelium, especially where its is leaky[7]. Sonication
with acceptable ultrasound intensity can then be used to
reform the original microbubbles, with their ligands intact.
This opens the way to imaging tissues beyond the
endothelium.
The simplest approach to therapy employing microbub-
bles is to make use of their mechanical vibrations[8] and
this has been used to accelerate thrombus breakdown to
promote revascularisation of the middle cerebral artery[9].
An interesting approach uses low ultrasound frequencies
and intensities along with microbubbles to ‘massage’ the
endothelium or other surfaces (remote palpation), relying
on the effect of acoustic radiation force impulses (ARFI)
to move microbubbles along the ultrasound beam[10].
This allows temporary opening of tight endothelial junc-
tions, for example to open the blood-brain barrier and
improve the penetration of co-administered i.v. drugs.
Co-administration obviates some of the regulatory bar-
riers to modified microbubbles and has been used to aug-
ment chemotherapy of pancreatic cancer with gemcitabine
[11]. Further such trials are anticipated. Microbubbles
might also be used to augment high intensity focussed
ultrasound (HIFU) which would speed up the method,
thus removing one of the main barriers to its wider use.Correspondence: d.csogrove@imperial.ac.uk
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The most direct approach to treatment with microbub-
bles is to tag them with active drugs such as chemothera-
peutic agents; breaking these microbubbles with high MI
pulses releases the agent so that high concentrations can
be achieved locally. This has been shown in small animals
to minimise the cardiotoxicity of adriamycin in breast can-
cer[12]. This therapeutic avenue could be combined with
the nanodroplets method and with remote palpation to
access tumours.
Thus, the diagnostic and therapeutic possibilities for
microbubbles are extensive; clinically useful approaches in
oncology can be anticipated in the not too distant future.
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